Form 4: Bioventus Director and 10% Owner Reports Significant Stock and RSU Transactions

John A. Bartholdson, a Director and 10% owner of Bioventus Inc., reported the acquisition of 26,493 shares of Class A Common Stock through RSU vesting and the grant of 32,282 new Restricted Stock Units.

Summary

• John A. Bartholdson, a Director and 10% owner of Bioventus Inc. (BVS), reported transactions involving the company's Class A Common Stock and Restricted Stock Units (RSUs).
• On June 2, 2025, Bartholdson acquired 26,493 shares of Class A Common Stock upon the vesting of previously granted RSUs. These shares were acquired at a price of $0, reflecting the nature of RSU conversion.
• Following this transaction, Bartholdson directly holds 72,045 shares of Class A Common Stock and indirectly holds 6,939,357 shares through various Juniper Entities.
• On June 3, 2025, Bartholdson was granted an additional 32,282 Restricted Stock Units (RSUs) at a price of $0.
• These newly granted RSUs are set to vest on the earlier of the day preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date, contingent on his continued service on the Board.

Sentiment

Score: 7

Explanation: The sentiment is positive as a director and 10% owner is increasing their direct ownership through RSU vesting and receiving new equity grants, indicating continued commitment and alignment with shareholder interests. No sales were reported.

Positives

• The acquisition of 26,493 shares of Class A Common Stock by a director and 10% owner through RSU vesting indicates a conversion of equity incentives into direct ownership, aligning management's interests with shareholders.
• The grant of an additional 32,282 Restricted Stock Units to a director suggests continued commitment and incentivization for long-term service and performance.

Future Outlook

The newly granted Restricted Stock Units are subject to future vesting, contingent on the reporting person's continued service on the Issuer's Board of Directors, indicating a future alignment of interests.

Industry Context

This Form 4 filing reflects routine equity compensation and ownership changes for a director and significant shareholder in the medical technology or orthobiologics industry, where equity incentives are common for aligning executive and board interests with company performance.

Related Party Transactions

• The indirect beneficial ownership of 6,939,357 shares is held through Juniper Entities (Juniper Targeted Opportunity Fund, L.P., Juniper Targeted Opportunities, L.P., and Juniper Multi-Strategy Fund, L.P.), where the reporting person, John A. Bartholdson, is a managing member of the general partners and investment manager, sharing voting and dispositive power. He disclaims beneficial ownership except for his pecuniary interest.

Stakeholder Impact

• Shareholders: The increase in direct ownership by a director and 10% owner through RSU vesting and the grant of new RSUs can be viewed positively as it aligns management's interests with those of shareholders, potentially signaling confidence in the company's future performance.

Next Steps

• The newly granted RSUs will vest on the earlier of the day preceding the Issuer's first Annual Meeting of Stockholders following the grant date or the first anniversary of the grant date.

Key Dates

Recommendation

Keywords

Bioventus Inc., BVS, SEC Form 4, Insider Trading, Stock Acquisition, Restricted Stock Units, RSU Vesting, Director Stock Ownership, 10% Owner, Equity Compensation, Juniper Entities